Fecal Calprotectin in Patients Infected with Intestinal Protozoan Infections

Not yet recruiting

• Conditions: Fecal Calprotectin in Intestinal Protozoa

• Registration Number: NCT06890455
• Lead Sponsor: Sohag University

Brief Summary

Calprotectin extracted from stool can be detected easily using ELISA. Numerous studies have shown that fecal calprotectin concentrations demonstrate a good correlation with intestinal inflammation This study aims to detect the relationship between fecal calprotectin and Blastocystis hominis and Entamoeba histolytica infections.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study Start: 2025-03
• Study First Submitted: 2025-03-17
• Study First Submitted QC: 2025-03-17
• Last Update Submitted: 2025-03-17
• Study First Posted: 2025-03-24
• Last Update Posted: 2025-03-24
• Primary Completion: 2025-10
• Study Completion: 2026-02

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

120 fecal samples will be collected as the following:

• 40 samples from patients complaining of gastrointestinal manifestations and only infected with B.hominis and E.histolytica.
• 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection.
• 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites).

Exclusion Criteria

• persons received antiparasitic drugs or antibiotic 2 weeks before sample collection Patients with mixed intestinal protozoa Patients with intestinal protozoa rather than Entamoeba histolytica and Blastocystis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of Blastocystis and Entamoeba	2 months

Secondary Outcome Measures

Name	Time	Method
Number of persons have high fecal calprotectin	6 months

Trial Locations

Locations (1)

Sohag University; 🇪🇬 Sohag, Egypt